Abstracts tagged "osteoarthritis and signal transduction"

Abstract Number: 1050 • 2014 ACR/ARHP Annual Meeting
A Role for Purinergic Receptor Signalling in Basic Calcium Phosphate Crystal-Induced Inflammation
Clare C. Cunningham¹, Emma M. Corr¹, Geraldine M. McCarthy² and Aisling Dunne¹, ¹School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland, ²Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Basic calcium phosphate (BCP) crystals are uniquely associated with osteoarthritis (OA). They are found in the majority of affected joints and closely correlate with…
Abstract Number: 40 • 2012 ACR/ARHP Annual Meeting
Syndecan-4 Regulates Activation of WNT Signaling in Chondrocytes
Jessica Bertrand¹, Richard Stange², Giovanna Nalesso³, Joanna Sherwood³, Lars Godmann⁴, Frank Echtermeyer⁵, Francesco Dell'Accio⁶ and Thomas Pap⁴, ¹Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, ²Dept. of Trauma, Hand and Reconstructive Surgery, University Hospital Münster, Münster, Germany, ³Centre for Experimental Medicine and Rheumatology, Queen Mary University London, London, United Kingdom, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany, ⁵Dept. of Anaesthesiology and Intensive Care Medicine, University hospital Hanover, Hanover, Germany, ⁶William Harvey Research Institute, Barts and the London Queen Mary's School of Medicine and Dentistry, Centre for Experimental Medicine and Rheumatology, London, United Kingdom
Background/Purpose: Blockade of syndecan-4 (Sdc4) signaling protects mice from cartilage degradation in experimentally induced osteoarthritis (OA). Cartilage damage results in changes of chondrocyte phenotype induced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].